Dan Horsey

Dan Horsey

Dan joins the Marketing team at Medable. Previously, Dan was a Content Manager at Signant Health and a Marketing Manager at IQVIA. He got his start in healthcare marketing in 2014, working with Pharmacy Benefits Managers in the managed Medicare and Medicaid spaces, and has been writing in healthcare capacities for over 10 years. Dan has extensive experience in creating both long and short forms of content across a wide variety of mediums. He earned his Bachelor of Arts in Communications from West Chester University in 2009. In his spare time, Dan composes music as a hobby and plays guitar for a Philadelphia based hardcore band.

Recent posts by Dan Horsey

2 min read

Highlights From Scope 2021, and the Clinical Trial Road Ahead

By Dan Horsey on Mar 17, 2021 12:44:02 PM

Those in the clinical trial industry understand that there are several barometers that can be used to gauge the overall state of the industry. Chief among these are the “big conferences” that occur each year, such as  SCOPE, J.P. Morgan week, and D.I.A.  

With another SCOPE behind us, we thought we’d take the time to summarize what we felt were some of the important industry trends and topics discussed in detail this year. 


An Increased Focus on Sensors in Trials

With the outside world still continuing to keep the majority of patients at home, a large focus at this year’s scope was on the promise and potential of sensors and wearables in the market. 

New ideas about the best ways to capture and use clinical trial data were bolstered by arguments showing the positive impact to drug development that comes from combining trial data with supplementary patient data. While the overall sentiment was positive and hopeful around the growing use of sensors, many cautioned that there would need to be a large concerted effort to centralize their deployment and standards of use with review boards and regulators worldwide. 

Presentation(s) of Note: 

Sensors and Wearables in a Decentralized World - Play back available now.
Ali Holland,Exec GM, Digital and Decentralized Solutions

Meeting all Endpoint Needs with a Single Platform
Geoff Gill, President, Shimmer Americas, Shimmer Research


The Growing World of Decentralized and Remote Trials

Continuing the sentiments of 2020, decentralization and remote trials continued to influence the conference at large. Many industry organizations touted their plans and capabilities when it came to administering trials at home, in-office, or anywhere in between. 

Furthermore, more companies were speaking to the general needs and circumstances that have led us towards decentralization. This includes not only COVID-19, but older research indicating how many patients, sites, and even sponsors are burdened and constrained by in-clinic only trials. 

Presentation(s) of Note: 

Scaling Decentralized Trials: Best Practices and Lessons Learned to Help Strengthen Patient-Centricity & Trial Delivery
Nagaraja (Sri) Srivatsan, Senior Vice President and Chief Digital Officer, Technology Solutions, IQVIA
Christopher Varner, Associate Director, Virtual Trials, IQVIA


The Effect of COVID-19 on Our Industry

For those who didn’t see this one coming, it only took a brief glance at this year’s agenda to know what would be a major talking point at this year’s SCOPE.

COVID-19 drove discussions pertaining to topics relevant across our entire industry. This included COVID as a driver for innovation, but also flexibility, speed, new ways of running trials, changing regulations, and the lasting legacy of clinical trials. 

Presentations of note:

Keynote Presentation: COVID-19: How an External Event Redoubled Janssen’s Culture of Innovation
Darren Weston, Vice President, Integrated Data Analytics & Reporting (IDAR), Janssen



As one could expect, several of the main themes of this year’s SCOPE were a direct result of our world in 2020. What SCOPE cemented, however, was that the “new norm” of doing things, one brought upon by COVID, is definitely here to stay.

3 min read

Recap: Industry Experts Discuss the Current and Future State of DCT - Insights from HCL Technologies' "Straight Talk" Session

By Dan Horsey on Mar 3, 2021 10:42:00 AM

On Thursday, February 24th, eight healthcare professionals from a coalition of clinical trial companies gathered on Twitter. Together, they were led through a series of questions about the impact, future, and value of decentralized clinical trials (DCTs) by HCL Technologies. 

Medable’s own Tyler Pugsley was one of eight professionals, answering questions from HCL and the live audience together in a new Twitter series known as “Straight Talk.” The blog below serves as a recap of key insights from their discussion.

Question 1 - How big a role will virtual/decentralized clinical trials play in future pharma R&D?

The group stated that virtual trials are here to stay now, having made a foothold in the industry prior to 2020, and becoming mainstream as a direct result of COVID. Thus, they will continue to play a vital role in the future of trials. 

When it came to discussing the role they will continue to play, many stated that DCT has a directly positive impact on trial access, as they expand the patient population pools out of specific geographic regions, and into the national level. Others discussed the benefits of passive data, and it’s combination with TeleHealth. Used appropriately, each has the ability to provide a clearer picture of a patient, their health, and how they’re progressing through a trial.

Finally, some highlighted the added benefits of speed, and reduced costs that come with the embrace and proliferation of services like TeleHealth, direct to patient labs, and more.

Question 2 - In what ways is the technology to support such clinical trials (DCTs) evolving?

The panel noted that technology is often a tool for removing barriers and improving communication with current solutions making trials more patient-centric, and opening access to anytime, anywhere clinical trial participation.

For instance, wearables have evolved to become smaller, less cumbersome, and better at passive data collection during the last few years. Other technologies have focused on closing the gaps between clinicians and patients, with real-time data helping clinicians understand how to facilitate ongoing patient engagement and manage health conditions.

Medable’s Tyler Puglsey, VP of Business Development and Growth laid out his vision for the future, as he believes the way we perceive patients will change over time to see them more as consumers of trials, and less participants.

Question 3 - How has COVID-19 changed the industry’s approach to adopting virtual/decentralized clinical trial platforms, instead of more traditional electronic data collection platforms (EDC)?

Here, many were quick to point out that COVID-19 seemed to remove many of the barriers towards DCT adoption almost overnight, noting that the pandemic highlighted what the industry could have looked like for some time.

Additionally, participants responded with the real world concerns brought on by the pandemic, noting that patients were unwilling to go onsite in many instances. The result? Televists, remote monitoring and more have become the “new normal” for many studies, as they provide an effective and safe way to interact with patients.

Question 4 - How can an organization transition to decentralized clinical trials at enterprise scale across its entire clinical research portfolio.

With this question, one panelist noted that the true barrier that must be overcome for enterprise scaling is culture. Focusing on technology alone, others suggested organizations begin by leaning into key components of DCT, such as online eConsent and eCOA that would allow for greater digital data collection.

Finally, some noted that these processes must be directly integrated into both the organization’s infrastructure and key processes in order to see the true benefits of data, workflow, and speed.

Question 5 - What long-term effect will such clinical trials (DCTs) have on drug development?

Many panelists noted that patient centered designs met with technology that increases convenience and mobility are here to stay. While many saw long-term gains in improving patient recruitment, engagement, and trial data. 

Others hoped to see the downfall of trial failure due to patient recruitment and dropout issues. 

With perhaps the clearest take on the industry’s future, our own Tyler Pugsley cut straight to the core of the issue, stating that “Let's break it down to the core objective: Speed to safe and effective drug approvals.”

2 min read

The First Step is Education: Medable’s Jennifer McNary nominated by Reuters for Her Work in Rare Disease Advocacy

By Dan Horsey on Dec 21, 2020 10:31:17 AM

“The reason the Master Class is happening is because advocates like myself were not given a roadmap when our children were diagnosed with rare diseases,” states Jennifer McNary, Rare Disease Advocate. She’s flanked virtually, by her peers and fellow patient advocates for Reuter’s Events 2020 Pharma awards.

Jennifer, alongside three other nominees, is being honored for her work in furthering patient advocacy. Jennifer supports the Patients Rising Master Class she mentions as a faculty member, which is facilitated by fellow Reuters nominee, Lilly Stairs, and is simply a part of her everyday work in furthering the education that exists for patients who suddenly find themselves at the tail end of a rare disease diagnosis.

For Jennifer, and many advocates like her, proper education is the first step in creating a roadmap towards treatment. “Really, the key is that when you have success, instead of keeping that to yourself, share it.”

Thankfully, Jennifer has been instrumental in creating roadmaps for rare diseases for years, most notably with Duchenne Muscular Dystrophy (DMD).  In fact, her work as the Director of Outreach and Advocacy at a Massachusetts based non-profit foundation is the reason for what was the largest FDA advisory committee hearing in history for DMD.

pasted image 0

Jennifer’s end goal? Better access to treatment and greater speed to cures.

“Approved doesn’t mean accessible,” Jennifer says. “There are so many disparities around who can participate in a trial. When my son was in a trial we were flying back and forth across the country every week for blood work.”

Thankfully, Jennifer acknowledges that those days are starting to change. Companies across the globe, such as Medable, where Jennifer chairs the Patient Advisory Council for 2020, are helping to bridge the gap between patients and trials. Home measurements, remote assessments and other technologies greatly increase access to trials that were previously only available to a select few.

Recently, advancements in DMD treatment have given advocates like her hope.  Yet, she acknowledges there is still much work to be done, not only in DMD, but in rare diseases with little to no treatment plans.  

“My hope for all the rare disease community is that we continue enhance flexibility at companies like ours, enhance education, and be prepared to provide access and reimbursement for these kinds of therapies,” Jennifer notes, “So that when someone is born with a rare disease in five years there’s a pre-established treatment plan to help them.”

To learn more about the Master Class, please visit the Patients Rising Now website here


About Jenn:

Jenn McNary is a trusted voice in the rare disease community, as a mother, public speaker and fierce advocate. Her work in the rare disease space as a thought leader earned her the Ryan’s Quest Ryan’s Hero award in 2013, a nomination for the Global Genes Champion of Hope award in 2014, and the prestigious 2017 Meyer- Whalley instrument of change award. Formerly as the director of outreach and advocacy at a Massachusetts based non-profit foundation, she was responsible for the organization of the largest FDA advisory committee hearing in history, with over 1000 Duchenne Muscular Dystrophy (DMD) advocates, families, clinicians and researchers in attendance.

Topics: life sciences DMD rare diseases
2 min read

Medable named “Life Sciences Innovation Champion” in the 2020 Accenture HealthTech Innovation Challenge

By Dan Horsey on Dec 17, 2020 12:48:07 PM

Medable is proud to announce we have been named “Life Sciences Innovation Champion” in the 2020 Accenture HealthTech Innovation Challenge. Accenture has recognized Innovation Champions since 2016, by inviting healthtech startups across the globe to demonstrate how they can bridge the gap between startups and life science companies to put innovation at the heart of their business and patents. This year, they invited life science startups to showcase their businesses and answer:

“How can we transform the patient experience prior, during or after care (at-home, outside of clinics)?”

Accenture selected Medable as Life Sciences Innovation Champion for the 2020 Accenture HealthTech Innovation Challenge for providing patients with an integrated digital and physical experience during clinical trials, allowing them to access clinical care sites and clinical trial teams from their mobile phones.

At Medable, we believe that healthcare works best when it’s designed to improve the lives of patients everywhere. Thus, we’re excited, humbled, and grateful to be recognized as a leading company that’s working to simplify clinical trials through decentralization, while providing greater access to patients across the globe. 

Our own Tyler Pugsley, VP of Life Science at Medable expresses our commitment to improving the clinical trial experience:

“We are extremely honored to receive this recognition from the Accenture HealthTech Innovation Challenge. Clinical innovation is only possible through the great contributions of patients. This recognition from Accenture allows us to further improve the patient experience so that any person, anywhere, can participate in a clinical trial.”


The Accenture HealthTech Innovation Challenge also showcases the breadth of advances happening every day across the life science ecosystem and recognizes more than just the hard work of Medable. It also honors the work of every startup in life sciences and the greater healthcare industry who has brought and inventive patient solutions to our market. This is especially true in 2020, as the industry works tirelessly to react and adapt to a world faced with new challenges and adversity as a direct result of the COVID-19 pandemic.

We’re also proud that so many of our peers have taken new and novel approaches towards solving the issues that continue to afflict our industry. So, if you have a moment, please take a second to recognize the following companies!

  • Cardiolyse, a cloud electrocardiogram (ECG) & heart rate variability (HRV) analytics platform that enables real-time remote heart health monitoring, providing plain-language personalized reports, detection and up to two months data-based prognosis on dangerous heart events;
  • Donisi, a global company at the forefront of contact-free health monitoring that works to change lives without changing lifestyles;
  • Particle Health, which is helping healthcare companies by offering simple, secure access to vital medical data by breaking down data silos that stunt innovation; and
  • Sidekick Health, which operates a patient-centric digital care platform driven by gamification and is scalable across a wide range of chronic illnesses.
Topics: decentralized trials DCT life sciences Innovation